<DOC>
	<DOCNO>NCT01025089</DOCNO>
	<brief_summary>The main purpose study find good bad effect combination cetuximab traditional chemotherapy regimen cisplatin , doxorubicin , cyclophosphamide give patient later stage thymoma thymic carcinoma surgery . The physician also look change gene tumor may relate effectiveness cetuximab</brief_summary>
	<brief_title>Chemotherapy Plus Cetuximab Followed Surgical Resection Patients With Locally Advanced Recurrent Thymoma Thymic Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Thymoma</mesh_term>
	<mesh_term>Thymus Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Age &gt; 18 Karnofsky Performance Status ( KPS ) ≥ 70 Newly diagnose recurrent thymoma WHO A , AB , B1 , B2 , B340 , thymic carcinoma pathologically confirm MSKCC , MDACC City Hope No prior chemotherapy , radiotherapy , surgical therapy ( diagnostic biopsy ) thymoma No prior treatment cetuximab Clinical Masaoka Stage II ( &gt; 5cm ) , III , IVA ( See Appendix B ) , include suspect invasion mediastinum , pericardium , lung , great vessel chest wall , and/or pleural metastasis Normal marrow function : leukocytes ≥ 4,000/μl , absolute neutrophil count ≥ 1,500/μl , platelet ≥ 160,000/μl Adequate renal function , creatinine ≤ 1.3 mg/dl calculate creatinine clearance ≥60ml/min Cockcroft Gault equation use parameter age , weight ( kg ) , baseline serum creatinine ( mg/dl ) Adequate hepatic function : Total bilirubin ≤1.5 mg/dl , AST ≤1.5X UNL , alkaline phosphatase ≤1.5 UN Signed inform consent Effective contraception Medically operable Evidence distant metastatic disease ( Masaoka stage IVB ) Thymic carcinoid Patients must receive investigational agent Concurrent prior malignancy last 5 year nonmelanoma skin cancer insitu carcinoma cervix Known HIVpositive patient receive combination antiretroviral therapy exclude study possible pharmacokinetic interaction study drug . Patients medication know alter CYP3A4 Pregnant breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Cetuximab</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>09-038</keyword>
</DOC>